MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202517074521 A) filed by Eli Lilly And Company, Indianapolis, on Aug. 5, for 'gip/glp1/gcg tri-receptor agonists and uses thereof.'
Inventor(s) include Abraham, Milata Mary; Brown, Robert Andrew; Coskun, Tamer; Flora, David Benjamin; Kleindl, Paul Joseph; Qu, Fucheng; Qu, Hongchang; and Wallis, James Lincoln.
The application for the patent was published on Sept. 12, under issue no. 37/2025.
According to the abstract released by the Intellectual Property India: "Polypeptides are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The polypeptides have structural features resulting in activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases and/or conditions such as obesity, chronic weight management, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, Chronic Kidney Disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS)."
The patent application was internationally filed on Jan. 31, 2024, under International application No.PCT/US2024/013645.
Disclaimer: Curated by HT Syndication.
